ZOMEDICA CORP (ZOM)
CA98980M1095 - Common Stock
We assign a fundamental rating of 4 out of 10 to ZOM. ZOM was compared to 195 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for ZOM as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ZOM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ZOM has reported negative net income.
ZOM had a negative operating cash flow in the past year.
In the past 5 years ZOM always reported negative net income.
ZOM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ZOM has a Return On Assets (-13.64%) which is in line with its industry peers.
With a decent Return On Equity value of -14.39%, ZOM is doing good in the industry, outperforming 62.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.64% | ||
| ROE | -14.39% | ||
| ROIC | N/A |
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ZOM has a better Gross Margin (68.76%) than 78.46% of its industry peers.
ZOM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZOM remains at a similar level compared to 1 year ago.
The number of shares outstanding for ZOM has been increased compared to 5 years ago.
ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.98 indicates that ZOM is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.98, ZOM is doing good in the industry, outperforming 79.49% of the companies in the same industry.
There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.98 |
ROIC/WACCN/A
WACC10.07%
2.3 Liquidity
A Current Ratio of 11.06 indicates that ZOM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.06, ZOM belongs to the top of the industry, outperforming 93.85% of the companies in the same industry.
A Quick Ratio of 10.49 indicates that ZOM has no problem at all paying its short term obligations.
ZOM's Quick ratio of 10.49 is amongst the best of the industry. ZOM outperforms 92.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.06 | ||
| Quick Ratio | 10.49 |
3. Growth
3.1 Past
The earnings per share for ZOM have decreased strongly by -102.88% in the last year.
Looking at the last year, ZOM shows a very strong growth in Revenue. The Revenue has grown by 33.05%.
EPS 1Y (TTM)-102.88%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-66.67%
Revenue 1Y (TTM)33.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q19.17%
3.2 Future
Based on estimates for the next years, ZOM will show a very strong growth in Earnings Per Share. The EPS will grow by 25.99% on average per year.
ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.89% yearly.
EPS Next Y56.09%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year37.23%
Revenue Next 2Y25.58%
Revenue Next 3Y25.89%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ZOM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZOM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZOM's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%
5. Dividend
5.1 Amount
ZOM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZOMEDICA CORP
NYSEARCA:ZOM (4/26/2024, 7:25:52 PM)
After market: 0.1338 +0 (+0.6%)0.133
+0 (+2.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap130.33M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.64% | ||
| ROE | -14.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.76% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.06 | ||
| Quick Ratio | 10.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-102.88%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y56.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)33.05%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y